Literature DB >> 32269168

Evaluation of the Reinforcing Strength of Phendimetrazine Using a Progressive-Ratio Schedule of Reinforcement in Rhesus Monkeys.

Molly Minkiewicz1, Paul W Czoty1, Bruce E Blough1, Michael A Nader2.   

Abstract

Stimulant abuse is a persistent public health problem with no Food and Drug Administration-approved pharmacotherapy. Although monoamine-releasing drugs such as d-amphetamine can decrease cocaine self-administration in human and animal laboratory studies, their potential for abuse limits clinical utility. "Abuse-deterrent" formulations of monoamine releasers, such as prodrugs, hold greater clinical promise if their abuse potential is, as theorized, lower than that of cocaine. In these studies, we determined the reinforcing strength of phendimetrazine (PDM), a prodrug for the amphetamine-like monoamine releaser phenmetrazine; both drugs have been shown to decrease cocaine self-administration in laboratory animals. To date, no study has directly compared PDM (Schedule III) with cocaine (Schedule II) under progressive-ratio (PR) schedules of reinforcement, which are better suited than fixed-ratio schedules to directly compare reinforcing strength of drugs. Dose-response curves for cocaine (saline, 0.001-0.3 mg/kg per injection) and PDM (0.1-1.0 mg/kg per injection) were generated in six cocaine-experienced male rhesus monkeys during 4-hour sessions with a 20-minute limited hold (LH). Under these conditions, the maximum number of injections was not significantly different between cocaine and PDM. The reinforcing strength of doses situated on the peaks of the cocaine and PDM dose-effect curves were redetermined with a 60-minute LH. The mean number of injections increased for both drugs, but not for saline. Cocaine presentations resulted in significantly higher peak injections than PDM with a 60-minute LH, which is consistent with the lower scheduling of PDM. These results support PDM as Schedule III and highlight the importance of schedule parameters when comparing reinforcing strength of drugs using a PR schedule of reinforcement. SIGNIFICANCE STATEMENT: One strategy for reducing cocaine use is to identify a treatment that substitutes for cocaine but has lower abuse potential. In a rhesus monkey model of drug abuse, this study compared the reinforcing strength of cocaine and phendimetrazine, a drug that has been shown to decrease cocaine use in some studies.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32269168      PMCID: PMC7288731          DOI: 10.1124/jpet.120.264952

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

Review 1.  Update on pharmacotherapy for treatment of opioid use disorder.

Authors:  Daniel Ayanga; Daryl Shorter; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2016-10-20       Impact factor: 3.889

2.  Interaction between behavioral and pharmacological treatment strategies to decrease cocaine choice in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2012-09-21       Impact factor: 7.853

3.  Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys.

Authors:  P W Czoty; B E Blough; T R Fennell; R W Snyder; M A Nader
Journal:  Neuroscience       Date:  2016-03-07       Impact factor: 3.590

4.  Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys.

Authors:  Paul W Czoty; Robert W Gould; Jennifer L Martelle; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2010-10-20       Impact factor: 7.853

5.  Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure.

Authors:  M A Nader; R H Mach
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

6.  Influence of phendimetrazine maintenance on the reinforcing, subjective, performance, and physiological effects of intranasal cocaine.

Authors:  William W Stoops; Justin C Strickland; Joseph L Alcorn; Lon R Hays; Abner O Rayapati; Joshua A Lile; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2019-03-21       Impact factor: 4.530

Review 7.  A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Authors:  Scott H Kollins
Journal:  Curr Med Res Opin       Date:  2008-04-01       Impact factor: 2.580

8.  Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats.

Authors:  Keri A Chiodo; David C S Roberts
Journal:  Psychopharmacology (Berl)       Date:  2009-08-04       Impact factor: 4.530

9.  Effects of phendimetrazine treatment on cocaine vs food choice and extended-access cocaine consumption in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; Timothy R Fennell; Rodney W Snyder; S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2013-07-30       Impact factor: 7.853

10.  Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys.

Authors:  Matthew L Banks; Bruce E Blough; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2013-05-31       Impact factor: 4.492

View more
  1 in total

1.  Chronic phenmetrazine treatment promotes D2 dopaminergic and α2-adrenergic receptor desensitization and alters phosphorylation of signaling proteins and local cerebral glucose metabolism in the rat brain.

Authors:  Bradley M Keegan; Annie L Dreitzler; Tammy Sexton; Thomas J R Beveridge; Hilary R Smith; Mack D Miller; Bruce E Blough; Linda J Porrino; Steven R Childers; Allyn C Howlett
Journal:  Brain Res       Date:  2021-02-23       Impact factor: 3.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.